BIIB241004P170000
- 0.23
- 0.000.00%
Biogen Newsroom
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal
Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug
Biogen to End Sage Deal for Neuro Candidate
Express News | Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the Sage-324 Program
Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the SAGE-324 Program
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study
Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Biogen Stock Touches 52-week Low at $189.44 Amid Challenges
Sector Update: Health Care Stocks Softer Wednesday Afternoon
Sector Update: Health Care
Biogen Sued by City of Baltimore Over Alleged Tecfidera Drug Pricing 'Scheme'
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $225 to $300
Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market
Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi
Express News | Biogen Shares up 2% Premarket After Co's Lupus Drug With Ucb Meets Main Goal of Late-Stage Trial
Eli Lilly's Alzheimer's Therapy Approved in Japan
Biogen (BIIB.US) and UCB's lupus new drug, daclizumab, late-stage trial successful, reversing early failures.
Baiqian and its Belgian partner UCB announced on Tuesday that their experimental lupus treatment drug, Dapirolizumab pegol, met the primary endpoint in late-stage trials.
Biogen, UCB Say Autoimmune Disease Drug Candidate Met Enpoint in Phase 3 Trial